Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
Hao Wang,1,2 Zhi-lin Sui,1 Xian-xian Wu,1 Peng Tang,1 Hong-dian Zhang,1 Zhen-tao Yu1,3 1Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of China; 2...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_7fb41e7b2eca48438a24c1b7a2a11f7d | ||
042 | |a dc | ||
100 | 1 | 0 | |a Wang H |e author |
700 | 1 | 0 | |a Sui Z |e author |
700 | 1 | 0 | |a Wu X |e author |
700 | 1 | 0 | |a Tang P |e author |
700 | 1 | 0 | |a Zhang H |e author |
700 | 1 | 0 | |a Yu Z |e author |
245 | 0 | 0 | |a Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
260 | |b Dove Medical Press, |c 2021-04-01T00:00:00Z. | ||
500 | |a 1178-7066 | ||
520 | |a Hao Wang,1,2 Zhi-lin Sui,1 Xian-xian Wu,1 Peng Tang,1 Hong-dian Zhang,1 Zhen-tao Yu1,3 1Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of China; 2Department of Surgical Oncology, Baotou Cancer Hospital, Baotou, People’s Republic of China; 3Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, People’s Republic of ChinaCorrespondence: Zhen-tao Yu; Hong-dian ZhangDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of ChinaTel +86 22-23340123Fax +86 22-23359984Email yuzhentao@tjmuch.com; zhdiantjzl@tmu.edu.cnObjective: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance.Methods: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis.Results: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance.Conclusion: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity.Keywords: miR-195-5p, NSCLC, cisplatin, chemosensitivity, FGF2 | ||
546 | |a EN | ||
690 | |a mir-195-5p | ||
690 | |a nsclc | ||
690 | |a cisplatin: chemosensitivity | ||
690 | |a fgf2 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmacogenomics and Personalized Medicine, Vol Volume 14, Pp 497-508 (2021) | |
787 | 0 | |n https://www.dovepress.com/reversal-of-chemotherapy-resistance-to-cisplatin-in-nsclc-by-mirna-195-peer-reviewed-fulltext-article-PGPM | |
787 | 0 | |n https://doaj.org/toc/1178-7066 | |
856 | 4 | 1 | |u https://doaj.org/article/7fb41e7b2eca48438a24c1b7a2a11f7d |z Connect to this object online. |